Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Differences in serum levels of soluble Fas and FasL in patients with human immunodeficiency virus, human herpesvirus type 8 and herpes simplex virus type 2 infections (CROSBI ID 578810)

Prilog sa skupa u zborniku | sažetak izlaganja sa skupa | međunarodna recenzija

Đaković-Rode, Oktavija ; Markotić, Alemka ; Kujundžić-Tiljak, Mirjana ; Židovec-Lepej, Snježana ; Begovac, Josip Differences in serum levels of soluble Fas and FasL in patients with human immunodeficiency virus, human herpesvirus type 8 and herpes simplex virus type 2 infections // 21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27th International Congress of Chemotherapy (ICC) - Online resurs. 2011. str. S650-S651

Podaci o odgovornosti

Đaković-Rode, Oktavija ; Markotić, Alemka ; Kujundžić-Tiljak, Mirjana ; Židovec-Lepej, Snježana ; Begovac, Josip

engleski

Differences in serum levels of soluble Fas and FasL in patients with human immunodeficiency virus, human herpesvirus type 8 and herpes simplex virus type 2 infections

Objectives: Fas mediated apoptosis is considered to be an important T cells depletion mechanism in HIV-infection. Soluble Fas (sFas) prevents apoptosis by inhibiting Fas binding with Fas ligand or soluble FasL (sFasL). We investigated possible differences in sFas and sFasL serum levels in HIV patients with herpes simplex type 2 (HSV-2) and human herpesvirus type 8 (HHV-8) coinfection. Methods: Levels of sFas and sFasL were measured by EIA in 136 HIV patients sera divided according to HHV-8 and HSV-2 antibody status. Four HIV patients groups were studied: 1) without HHV-8 and HSV-2 (n=48), 2) with HHV-8 and HSV-2 (n=21), 3) with only HSV-2 (n=61), 4) with only HHV-8 (n=6). HIV-negative persons (n=39) without HHV-8 and HSV-2 and HIV-negative with HSV- 2 antibodies (Ab) (n=20) served as controls. In statistical analyses we used the Kruskal-Wallis and Mann-Whitney-Wilcoxon tests. The Bonferroni correction was applied for pairwise comparisons. Results: The median concentrations of sFas and sFasL were: 589.3 pg/ml and 47.8 pg/ml in HIV patients without HHV-8 and HSV-2 ; 892.3 pg/ml and 72.2 pg/ml in HIV patients with HHV-8 and HSV-2 ; 717.6 pg/ml and 40.9 pg/ml in HIV patients with only HSV-2 ; 1010.6 pg/ml and 70.9 pg/ml in HIV patients with only HHV-8 ; 678.9 pg/ml and 61.4 pg/ml in HIV-negative controls ; 695.2 pg/ml and 59.9 pg/ml in HIV-negative controls with HSV-2. Higher sFas and sFasL levels were found in HIV patients with HHV-8 and HSV-2 compared to HIV patients without HHV-8 and HSV-2 Ab (P<0.001 ; P=0.001, respectively) and also compared to HIV patients with only HSV-2 Ab (P 0.034 ; P<0.001, respectively). Higher sFas was also found in HIV patients with HHV-8 and HSV-2 Ab compared to HIV- negative controls without HHV-8 and HSV-2 Ab (P=0.046). HIV patients with only HHV-8 Ab had higher sFas than HIV patients without HHV-8 and HSV-2 Ab (P=0.006). Lower sFasL levels were found in HIV patients with only HSV-2 Ab than in HIV- negative controls with and without HSV-2 Ab (P=0.001 ; P<0.001, respectively). Conclusion: Our results suggest that HHV-8 and HSV-2 infections may mediate apoptosis signalling molecules sFas and sFasL. The increased sFas concentrations found in HIV patients with positive HHV-8 and HSV-2 Ab suggest suppression of Fas mediated apoptosis. Our findings need to be confirmed by additional in vitro data and further studies are necessary to define the clinical significance of these findings.

HIV; soluble Fas and FasL; HHV8; HCV type 2

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

S650-S651.

2011.

objavljeno

Podaci o matičnoj publikaciji

21st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), 27th International Congress of Chemotherapy (ICC) - Online resurs

Podaci o skupu

21st European Congress of Clinical Microbiology and Infectious Diseases 27th International Congress of Chemotherapy

poster

07.05.2011-10.05.2011

Milano, Italija

Povezanost rada

Kliničke medicinske znanosti